Our site will be undergoing maintenance Saturday June 3 (midnight) through Sunday June 4 (noon). During that time, our login will not be available. Thank you for your patience.
Focus on COVID-19 Prevention Intensifies for Patients With Cancer as FDA Removes Emergency Use Authorization for Evushield
Kathleen Wiley, RN, MSN, AOCNS®
On January 26, 2023 the U.S. Food and Drug Administration (FDA) removed its emergency use authorization (EUA) of tixagevimab/cilgavimab (Evushield) for the prevention of SARS-CoV-2 infection after exposure to the virus. FDA said it made the decision because the agent is not effective in preventing infections from the current variants that are responsible for 90% of today’s infections and because the risks of the drug’s side effects do not outweigh the benefits.